摘要
回顾性分析郑州大学人民医院2019年8月至2020年8月初治Ⅲ/Ⅳ期结外NK/T细胞淋巴瘤(ENKTL)患者资料。9例患者采用了程序性死亡受体1(PD-1)抑制剂联合P-Gemox-Dex(吉西他滨+奥沙利铂+地塞米松+培门冬酶)方案作为一线治疗方案,4周期治疗结束后,采用正电子发射计算机断层扫描(PET/CT)评估疗效,并观察不良反应。9例患者中位随访时间为7个月,总有效率为9/9,完全缓解6例,部分缓解3例。主要不良事件为血液学毒性,6例患者出现Ⅰ~Ⅱ度中性粒细胞减少,未见免疫相关的不良事件。
The data of 9 patients with stageⅢ/Ⅳextranodal nasal-type natural killer/T cell lymphoma from August 2019 to August 2020 in People′s Hospital of Zhengzhou University was retrospectively analyzed.All the patients were treated with the programmed cell death-1(PD-1)inhibitor combined with P-GemoX-DEX(gemcitabine+oxaliplatin+dexamethasone+peraspartase)regimen as the first-line treatment.After 4 cycles of treatment,positron emission tomography/computed tomography(PET/CT)was used to evaluate the curative effect,and adverse reactions were also observed.The median follow-up time was 7 months.The overall response rate,complete and partial remission rate was 9/9,6/9 and 3/9,respectively.The main adverse event was hematological toxicity,with 6 cases of gradeⅠ/Ⅱneutropenia,and no immune-related adverse events were reported.
作者
刘渊博
袁晓莉
马荣军
姜丽
王力夫
朱尊民
Liu Yuanbo;Yuan Xiaoli;Ma Rongjun;Jiang Li;Wang Lifu;Zhu Zunmin(Department of Hematology,People′s Hospital of Zhengzhou University,Institute of Hematology,Henan Provincial People′s Hospital,Zhengzhou 450003,China;Department of Pathology,People′s Hospital of Zhengzhou University,Zhengzhou 450003,China)
出处
《中华医学杂志》
CAS
CSCD
北大核心
2021年第16期1178-1181,共4页
National Medical Journal of China
